Online supplemental table 1. Summary of variables included in the PRESTIGIO Registry


from the date of evidence of 4-class drug resistance.

date of birth, sex at birth, country of birth, ethnicity
height, weight, smoking habit
mode of HIV transmission, date of last negative HIV test, date of first
positive HIV test, date of 4-class drug resistance
HIV-1 RNA (copies/mL), HIV-1 RNA before ART start (copies/mL)
$CD4^{\scriptscriptstyle +}$ T-cell count (cells/µL, %), $CD8^{\scriptscriptstyle +}$ T-cell count (cells/µL, %),
CD4 ⁺ /CD8 ⁺ ratio, CD4 ⁺ nadir (cells/µL)
RNA- and DNA-based genotypic resistance testing (collected since the
first test available, also before evidence of 4-class drug resistance)
subtype, viral tropism (collected since the first available, also before
evidence of 4-class drug resistance)
hepatitis B and C serologies, HBV DNA, HCV RNA
complete blood cell count
plasma glucose, triglycerides, total/HDL-/LDL-cholesterol, creatinine,
transaminases, direct and indirect bilirubin
date of antiretroviral therapy start, date of highly active antiretroviral
therapy (defined as a combination of drugs from at least 2 different
classes) start

regimens from baseline to the last available visit (including start and
stop dates, dose and mode of administration, reason for switch)
specific drugs (including start and stop dates, dose and mode of
administration, reason for stop)
date and type of vaccinations
date and type of AIDS events
non-AIDS malignancies, diabetes, arterial hypertension requiring
treatment, major adverse cardiovascular events, chronic liver or kidney
diseases, osteoporosis and related fractures, neurocognitive disorders,
chronic obstructive pulmonary disease, etc. (including dates of
diagnosis and eventually resolution)
dates and reason for hospitalization
dates of pregnancy, date of delivery, etc.
date of diagnosis, type, and treatment of sexually transmitted infections
date and reason of death

BMJ Open

Online supplemental figure 1. Resistance-associated mutations present in ≥20% of 4DR-PLWH from the PRESTIGIO Registry. All RNA-based genotypic resistance tests through Sanger sequencing were considered cumulatively. Percentages evaluated on 229 PLWH for NRTI, NNRTI, and PI resistance-associated mutations, on 175 PLWH with at least one available integrase genotype for INSTI resistance-associated mutations. INSTI: integrase strand transfer inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; 4DR-PLWH: people living with 4-class drug-resistant HIV.



Resistance-associated mutations